CanGaroo
Commercial- Indications
- Cardiac implant protection
Company intelligence / Profile preview
Elutia
Silver Spring, Maryland, United Stateselutia.com ↗
- Ownership
- Public · ELUT
- Employees
- ~51
- Development stage
- Commercial
01
Overview
Elutia has commercialized two main product lines—CanGaroo and SimpliDerm—both leveraging its proprietary drug-eluting biomaterial platform. CanGaroo provides an acellular envelope for cardiac devices to reduce infection and fibrotic response; SimpliDerm serves as a human acellular dermal matrix for soft tissue repair. The company’s new product, EluPro, recently received FDA clearance and competes directly with Medtronic’s TYRX in the antibiotic-eluting envelope market. Clinical data suggest that using natural biologics instead of synthetic polymers leads to better remodeling into healthy tissue and less scar formation.
- Therapeutic areas
- OtherCardiovascularNeurology
- Modalities
- Drug-eluting biomaterialsAcellular biologic matrices
- Industry
- Implantable Medical Devices
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $35.4M
- Total revenue
- $2.4M
- Enterprise value
- $26.3M
Beyond the preview
Go deeper on Elutia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elutia.